BHL launches ‘Posaconazole API’ for treating Mucormycosis infections in Covid-19 patients

Mumbai : Bajaj Healthcare Limited (BHL), one of the leading manufacturer of APIs, Intermediates and Formulations, has announced the launch of “Posaconazole API” used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients.

BHL has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market “Posaconazole API” as approved medication for treating Mucormycosis in India and it will commence its commercial production from 1st week of June 2021.

Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post Covid complications.

Commenting on the launch of “Posaconazole API”, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said “We are pleased to add Posaconazole API to our growing product portfolios. The second waves of coronavirus is more aggressive and bigger in number than the first According to Doctors the fungal infection that has emerged during the second wave has been widely linked with excessive usage of steroids and uncontrolled diabetes in coronavirus positive patients. We hope the availability of an effective treatment such as Posaconazole will considerably ease the pressure and offer patients much needed and timely therapy option.”

BHL has successfully developed the active pharmaceutical ingredient (API) for Posaconazole through its own in-house R&D team. The drug will be available as a prescription-based medication, with recommended doses.

The FDA Gandhi Nagar, Gujarat (India) has granted permissions to manufacture and market the “Posaconazole API” in the domestic as well as overseas market.